Roivant Sciences (ROIV) Receivables - Net (2021 - 2024)
Roivant Sciences' (ROIV) quarterly Receivables - Net came in at $678000.0 in Q4 2024, down 98.35% on a YoY basis from $41.1 million in Q1 2024, and down 64.61% quarter-over-quarter from $1.9 million in Q3 2024.
Analysis
Roivant Sciences (ROIV) Receivables - Net (2021 - 2024) Analysis & Trends
Roivant Sciences (ROIV) has reported Receivables - Net for 4 consecutive years, with $678000.0 the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Receivables - Net fell 98.35% year-over-year to $678000.0; the trailing twelve-month figure through Dec 2024 stood at $678000.0 (down 98.35% YoY), and the FY2024 full-year result was $678000.0, down 98.35% from the prior year.
- Receivables - Net declined to $678000.0 in Q4 2024 per ROIV's latest filing, from $1.9 million in the prior quarter.
- Across five years, Receivables - Net topped out at $79.8 million in Q2 2024 and bottomed at $678000.0 in Q4 2024.
- Historically, Receivables - Net has averaged $22.5 million across 4 years, with a median of $11.2 million in 2021.
- The sharpest annual moves came in 2023 and 2024: Receivables - Net surged 683.37% in 2023, then tumbled 98.35% in 2024.
- Over 4 years, Receivables - Net stood at $8.9 million in 2021, then jumped by 213.5% to $28.0 million in 2022, then jumped by 46.88% to $41.1 million in 2023, then sank by 98.35% to $678000.0 in 2024.
- According to Business Quant data, Receivables - Net over the past three periods registered $678000.0, $1.9 million, and $79.8 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.68 Bn | 197.69 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.84 Bn | 177.66 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.30 Bn | 124.45 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.50 Bn | 74.50 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.49 Bn | 56.31 Bn | 1.37 Bn |
| 6 | Moderna | 55.01 Bn | 49.87 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.08 Bn | 30.77 Bn | 992.69 Mn |
| 8 | Biogen | 31.35 Bn | 30.06 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.87 Bn | 29.87 Bn | 1.16 Mn |
| 10 | Insmed | 27.84 Bn | 26.68 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 678,000.00 |
| Sep 30, 2024 | 1.92 Mn |
| Jun 30, 2024 | 79.79 Mn |
| Mar 31, 2024 | 3.99 Mn |
| Dec 31, 2023 | 41.08 Mn |
| Sep 30, 2023 | 52.12 Mn |
| Jun 30, 2023 | 37.06 Mn |
| Mar 31, 2023 | 30.38 Mn |
| Dec 31, 2022 | 27.97 Mn |
| Sep 30, 2022 | 25.04 Mn |
| Mar 31, 2022 | 3.88 Mn |
| Dec 31, 2021 | 8.92 Mn |
| Sep 30, 2021 | 9.81 Mn |
| Jun 30, 2021 | 3.42 Mn |
| Mar 31, 2021 | 11.22 Mn |